Luminex Corporation provided consolidated earnings guidance for the fourth quarter, full year of 2018 and full year of 2019. For the fourth quarter, the company expects its revenues to be approximately $81 million. The company expects its revenues to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million. In 2019, the company expects consolidated revenue to be between $337 and $343 million, which includes revenue from the flow cytometry business purchased from MilliporeSigma; an approximate $35 million decline in LabCorp purchases of Molecular Diagnostic products.